- Home
- NKTR vs HRTX Comparison
NKTR vs HRTX Comparison
Compare NKTR & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- HRTX
- Stock Information
- Founded
- NKTR 1990
- HRTX 1983
- Country
- NKTR United States
- HRTX United States
- Employees
- NKTR N/A
- HRTX N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- NKTR Health Care
- HRTX Health Care
- Exchange
- NKTR Nasdaq
- HRTX Nasdaq
- Market Cap
- NKTR 247.9M
- HRTX 270.7M
- IPO Year
- NKTR 1994
- HRTX 1987
- Fundamental
- Price
- NKTR $0.93
- HRTX $1.73
- Analyst Decision
- NKTR Strong Buy
- HRTX Strong Buy
- Analyst Count
- NKTR 5
- HRTX 3
- Target Price
- NKTR $4.50
- HRTX $5.67
- AVG Volume (30 Days)
- NKTR 3.0M
- HRTX 1.2M
- Earning Date
- NKTR 03-07-2025
- HRTX 02-27-2025
- Dividend Yield
- NKTR N/A
- HRTX N/A
- EPS Growth
- NKTR N/A
- HRTX N/A
- EPS
- NKTR N/A
- HRTX N/A
- Revenue
- NKTR $93,137,000.00
- HRTX $137,737,000.00
- Revenue This Year
- NKTR $12.15
- HRTX $13.10
- Revenue Next Year
- NKTR N/A
- HRTX $14.03
- P/E Ratio
- NKTR N/A
- HRTX N/A
- Revenue Growth
- NKTR 5.53
- HRTX 12.13
- 52 Week Low
- NKTR $0.63
- HRTX $1.04
- 52 Week High
- NKTR $1.93
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- NKTR 53.83
- HRTX 52.86
- Support Level
- NKTR $0.92
- HRTX $1.63
- Resistance Level
- NKTR $1.08
- HRTX $1.83
- Average True Range (ATR)
- NKTR 0.09
- HRTX 0.10
- MACD
- NKTR 0.03
- HRTX -0.01
- Stochastic Oscillator
- NKTR 65.63
- HRTX 41.94
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.